VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00049686
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 18, 2013
Information provided by:
National Cancer Institute (NCI)

November 12, 2002
January 27, 2003
July 18, 2013
April 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00049686 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome.


  • Determine the toxic effects of VNP40101M in patients with relapsed or refractory leukemia or poor-risk myelodysplastic syndromes.
  • Determine the maximum tolerated dose of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the antitumor effects of this drug in these patients.

OUTLINE: Patients receive VNP40101M IV over 15 minutes once every 4 weeks.

PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.

Phase 1
Masking: None (Open Label)
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
Drug: laromustine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
January 2008
Not Provided


  • Relapsed or refractory leukemia for which no standard therapy is anticipated to result in a durable remission OR
  • Poor-risk myelodysplastic syndromes



  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Not specified


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 3 times ULN


  • Creatinine no greater than 2.0 mg/dL


  • No myocardial infarction within the past 3 months
  • No symptomatic coronary artery disease
  • No uncontrolled arrhythmia
  • No uncontrolled congestive heart failure


  • No uncontrolled active infection


Biologic therapy

  • Prior biologic therapy allowed


  • At least 2 weeks since prior myelosuppressive cytotoxic chemotherapy in the absence of rapidly progressing disease
  • At least 48 hours since prior hydroxyurea

Endocrine therapy

  • Not specified


  • Prior radiotherapy allowed


  • Not specified


  • No other concurrent standard or investigational treatment for leukemia
  • No concurrent disulfiram
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000258354 ( Registry Identifier: PDQ (Physician Data Query) )
Not Provided
Not Provided
Not Provided
Not Provided
Vion Pharmaceuticals
Not Provided
Study Chair: Mario Sznol, MD Vion Pharmaceuticals
National Cancer Institute (NCI)
September 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP